We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > fluvoxamine

News List

Fluvoxamine may prevent severe COVID-19 onset, suggests trial europeanpharmaceuticalreview
November 17, 2020
Researchers say the promising results warrant larger trials evaluating fluvoxamine as a potential intervention to prevent COVID-19 patients developing severe symptoms.
Fluvoxamine may prevent serious illness in COVID-19 patients worldpharmanews
November 16, 2020
In a preliminary study of COVID-19 patients with mild-to-moderate disease who were attempting to recover in their homes, researchers at Washington University School of Medicine in St. Louis have found that the drug fluvoxamine seems to prevent some of ...
JAMA Reports Fluvoxamine as Potential Early Treatment for COVID-19 prnewswire
November 13, 2020
The COVID-19 Early Treatment Fund (CETF), announced that JAMA, The Journal of the American Medical Association, published the results of a Washington University School of Medicine in St. Louis double-blind, randomized controlled clinical trial that ...
Trial supports use of fluvoxamine in patients with mild COVID-19 europeanpharmaceuticalreview
October 16, 2020
A clinical trial has demonstrated that the likelihood of hospitalisation was significantly reduced for patients with mild COVID-19 when given fluvoxamine.